Page 60 - TD-4-2

Tumor Discovery Role of honokiol in combination therapy

in combination with systemic paclitaxel for synergistic Sci. 2023;18(5):580-591.
therapy of breast cancer. Eur J Pharm Sci. 2022;175:106212.
doi: 10.4103/1735-5362.383712
doi: 10.1016/J.EJPS.2022.106212
51. Froudarakis M, Hatzimichael E, Kyriazopoulou L, et al.
41. Kalyanaraman B. Teaching the basics of the mechanism of Revisiting bleomycin from pathophysiology to safe clinical
doxorubicin-induced cardiotoxicity: Have we been barking use. Crit Rev Oncol Hematol. 2013;87(1):90-100.
up the wrong tree? Redox Biol. 2020;29:101394.
doi: 10.1016/J.CRITREVONC.2012.12.003
doi: 10.1016/J.REDOX.2019.101394
52. Gowda ASP, Suo Z, Spratt TE. Honokiol inhibits DNA
42. Pillai VB, Kanwal A, Fang YH, et al. Honokiol, an activator polymerases β and λ and increases bleomycin sensitivity of
of sirtuin-3 (SIRT3) preserves mitochondria and protects human cancer cells. Chem Res Toxicol. 2017;30(2):715-725.
the heart from doxorubicin-induced cardiomyopathy in doi: 10.1021/ACS.CHEMRESTOX.6B00451
mice. Oncotarget. 2017;8(21):34082.
53. Pearson HE, Iida M, Orbuch RA, et al. Overcoming
doi: 10.18632/ONCOTARGET.16133
resistance to cetuximab with honokiol, a small-molecule
43. Huang L, Zhang K, Guo Y, et al. Honokiol protects against polyphenol. Mol Cancer Ther. 2018;17(1):204-214.
doxorubicin cardiotoxicity via improving mitochondrial doi: 10.1158/1535-7163.MCT-17-0384
function in mouse hearts. Sci Rep. 2017;7(1):11989.
54. Khera N, Rajput S. Therapeutic potential of small molecule
doi: 10.1038/s41598-017-12095-y
inhibitors. J Cell Biochem. 2017;118(5):959-961.
44. Yi X, Lou L, Wang J, Xiong J, Zhou S. Honokiol antagonizes
doxorubicin resistance in human breast cancer via miR- doi: 10.1002/JCB.25782
188-5p/FBXW7/c-Myc pathway. Cancer Chemother 55. Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule
Pharmacol. 2021;87(5):647-656. inhibitors targeting the cancers. MedComm (2020).
2022;3(4):e181.
doi: 10.1007/S00280-021-04238-W
doi: 10.1002/MCO2.181
45. Thulasiraman P, Johnson AB. Regulation of Mucin 1 and
multidrug resistance protein 1 by honokiol enhances the 56. Leeman-Neill RJ, Cai Q, Joyce SC, et al. Honokiol inhibits
efficacy of doxorubicin-mediated growth suppression in epidermal growth factor receptor signaling and enhances
mammary carcinoma cells. Int J Oncol. 2016;49(2):479-486. the antitumor effects of epidermal growth factor receptor
inhibitors. Clin Cancer Res. 2010;16(9):2571-2579.
doi: 10.3892/IJO.2016.3534
doi: 10.1158/1078-0432.CCR-10-0333
46. Ghafouri-Fard S, Abak A, Tondro Anamag F, et al.
5-fluorouracil: A narrative review on the role of regulatory 57. Rawat L, Balan M, Sasamoto Y, Sabarwal A, Pal S. A novel
mechanisms in driving resistance to this chemotherapeutic combination therapy with cabozantinib and honokiol
agent. Front Oncol. 2021;11:658636. effectively inhibits c-Met-Nrf2-induced renal tumor
growth through increased oxidative stress. Redox Biol.
doi: 10.3389/FONC.2021.658636
2023;68:102945.
47. Ji N, Jiang L, Deng P, et al. Synergistic effect of honokiol and
5‐fluorouracil on apoptosis of oral squamous cell carcinoma doi: 10.1016/J.REDOX.2023.102945
cells. J Oral Pathol Med. 2017;46(3):201-207. 58. Kumar R, Goel H, Solanki R, et al. Recent developments in
receptor tyrosine kinase inhibitors: A promising mainstay in
doi: 10.1111/JOP.12481
targeted cancer therapy. Med Drug Discov. 2024;23:100195.
48. Lee MY, Shi CS, Hsu YC, et al. Honokiol is a potential doi: 10.1016/J.MEDIDD.2024.100195
therapeutic agent and has a synergistic effect with 5-FU
in human urothelial cell carcinoma cells. Anticancer Res. 59. Wang Y, Yang Z, Zhao X. Honokiol induces paraptosis
2019;39(12):6555-6565. and apoptosis and exhibits schedule-dependent synergy in
combination with imatinib in human leukemia cells. Toxicol
doi: 10.21873/ANTICANRES.13871
Mech Methods. 2010;20(5):234-241.
49. Swidan SA, Hassan MM, Elmansy MN, Swidan SA.
Synergistic therapeutic effect of nano-honokiol and doi: 10.3109/15376511003758831
5-fluorouracil on the induced-tongue cancer in rats. J Oral 60. Song JM, Anandharaj A, Upadhyaya P, et al. Honokiol
Maxillofac Surg Med Pathol. 2020;32(6):556-562. suppresses lung tumorigenesis by targeting EGFR and its
downstream effectors. Oncotarget. 2016;7(36):57752-57769.
doi: 10.1016/J.AJOMS.2020.06.003
doi: 10.18632/ONCOTARGET.10759
50. Mikhaevich E, Sorokin D, Scherbakov A. Honokiol inhibits
the growth of hormone-resistant breast cancer cells: Its 61. Zang H, Qian G, Arbiser J, et al. Overcoming acquired
promising effect in combination with metformin. Res Pharm resistance of EGFR-mutant NSCLC cells to the third

Volume 4 Issue 2 (2025) 52 doi: 10.36922/td.8152